Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04584372
Other study ID # UVienna_Dietary nitrate
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2021
Est. completion date March 28, 2023

Study information

Verified date May 2023
Source University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The risk for cardiovascular diseases (CVD) increases with advancing age. Developing effective lifestyle-based strategies to promote, preserve or restore cardiovascular health with aging is a high priority. The overall aim of this clinical research is to investigate the innovative concept that an increased intake of dietary nitrate (through beetroot juice) could be a feasible adjuvant therapy to treat elevated blood pressure and improve blood vessel function in older adults. Inorganic dietary nitrate, found in beetroot and green leafy vegetables, is a source of nitric oxide (NO), a signaling molecule that is important for cardiovascular health. NO is also produced in the human body, but the body's production and availability of NO decrease during ageing and CVD. The declined NO availability is associated with impaired blood vessel function, unresolved inflammatory responses, and an increased CVD risk. Dietary nitrate is an additional NO source. Following the intake of nitrate, NO is produced in a pathway that involves commensal bacteria in the mouth. So far, little is known about whether dietary nitrate improves cardiovascular health in older populations with high blood pressure. The aim of this randomized, placebo-controlled crossover study is to investigate whether the daily intake of nitrate-rich beetroot juice over four weeks translates into improved cardiovascular health-related outcomes in older adults with treated mild high blood pressure. Men and women, between the ages of 55 and 70 years, who have been diagnosed with grade 1 high blood pressure and who are taking two or more blood-pressure lowering medications will be recruited. The study will investigate whether the increased dietary nitrate intake further lowers blood pressure and improves blood vessel function. A specific aim is to examine whether the nitrate intake results in favorable changes in the oral bacteria community and the systemic inflammatory status, and whether these changes correlate with cardiovascular-related outcomes. This research will offer information on the value of dietary nitrate to counteract chronic inflammation, the latter of which plays a role in developing or worsening cardiovascular disorders, such as high blood pressure. The expected results of this study will provide important new evidence of whether nitrate-rich beetroot juice could be a key component of therapeutic interventions to improve cardiovascular health in individuals with high blood pressure.


Description:

This clinical research is funded by the Austrian Science Fund (FWF, project number: KLI 858). It is based on close collaborations between the University of Vienna and the Medical University of Vienna, with the Department of Clinical Pharmacology at the Medical University of Vienna as the clinical trial center and Prof. M.D. Michael Wolzt as the trial center's coordinating physician. The sponsor is the University of Vienna, as represented by the Principal Investigator Dr. Oliver Neubauer (Research Platform Active Ageing). International collaborations include Dr. Catherine Bondonno, Prof. Hodgson (both Edith Cowan University) Dr. Jonathan Peake (Queensland University of Technology), and Prof. Richard Woodman (Flinders University) (all Australia). Wider research context / theoretical framework: Aging is a major risk factor for cardiovascular disease (CVD). Developing effective strategies to improve cardiovascular health with ageing is a high priority. Emerging data indicate that inorganic dietary nitrate, found in green leafy vegetables and beetroot juice (BRJ), is important for cardiovascular health (Blekkenhorst et al. 2018). These data suggest that small increases in nitrate intake among those with elevated risk for CVD would have a substantial impact, by improving the bioavailability of nitric oxide (NO) through the enterosalivary nitrate- nitrite-NO pathway (involving the oral microbiome). Results from the study group's research suggest beneficial short-term effects of nitrate-rich BRJ on blood pressure and vascular inflammation markers in healthy older adults (Raubenheimer et al. 2017). Hypotheses / research questions / objectives: The proposed clinical study is aimed to examine whether the daily consumption of 2×70 mL BRJ over 4 weeks translates into improved clinical outcomes in older adults with treated grade 1 hypertension. The primary hypothesis is that the increased dietary nitrate intake lowers blood pressure and improves vascular function. The secondary hypotheses are that the increased dietary nitrate intake results in changes in the oral microbiome, favorably modulates the systemic inflammatory status, and that these changes correlate with cardiovascular-related outcomes. Approach / methods: This randomized, placebo-controlled crossover study will involve two 4-week treatment periods, consisting of interventions with nitrate-rich BRJ and nitrate-depleted BRJ, separated by a 4-week washout period. Thirty-five men and women, between the ages of 55 and 70 years, who have been diagnosed with grade 1 hypertension will be recruited. Twenty-nine participants will be required to complete the study, based on power/sample size calculations with the forearm blood flow (FBF) response to acetylcholine and 24 h-ambulatory systolic blood pressure as the primary endpoints. Principal secondary endpoints are the number of CD11b-expressing blood granulocytes and the FBF response to glyceryltrinitrate. Among various additional secondary and exploratory endpoints, plasma nitrate and nitrite and a broad range of inflammation biomarkers will be measured. Furthermore, the oral microbiome will be analyzed. Level of originality / innovation: Beneficial effects of nitrate have predominantly been observed in healthy populations, but evidence of cardiovascular benefits and anti-inflammatory effects in clinical populations is limited (Raubenheimer et al. 2019). This study addresses the need to determine the efficacy of dietary nitrate to improve cardiovascular health and counteract chronic low-grade inflammation in humans at risk of CVD.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date March 28, 2023
Est. primary completion date March 28, 2023
Accepts healthy volunteers No
Gender All
Age group 55 Years to 75 Years
Eligibility Inclusion Criteria: - Ambulant male and females between 55 and 75 years of age, inclusive - Resting systolic blood pressure between 130 and 170 mmHg, inclusive - Written informed consent Exclusion Criteria: - Diastolic blood pressure >110 mmHg - Type 1 or 2 diabetes mellitus or fasting glucose >7.0 mmol/L - Any evidence of acute or chronic disease such as symptomatic cardiovascular or peripheral vascular disease, moderate or severe chronic kidney disease (estimated glomerular filtration rate (GFR) <50 ml/min)), or cancer which is not in remission - Consumption of =5 serves of vegetables per day - Consumption of a diet estimated to contain >200 mg/d of nitrate - Being vegan or vegetarian - BMI =35 kg/m2 or <18.5 kg/m2 - Use of nitric oxide donors, organic nitrites/nitrates, sildenafil and related drugs, anti-coagulation, non-steroidal anti-inflammatory or statin-related drugs - Use of antibacterial mouthwash (volunteers willing to cease using antibacterial mouth wash for a period of 4 weeks before randomisation will be included) - Use of antibiotics (within previous 2 months) - A change in drug therapy likely to influence blood pressure or major secondary outcomes within the previous month, or the likelihood that drug therapy would change during the study - Current or recent (within previous 3 months) engagement in regular structured exercise training (more than 2 hours of moderate to more intense exercise per week) - Current or recent (within previous 6 months) loss or gain of >6% of body weight - Current or recent (<12 months) regular smoking of >5 cigarettes/day - Alcohol intake >140 g per week for women or >210 g per week for men and/or binge drinking behaviour - Inability or unwillingness to follow the study protocol - Pregnancy or lactation

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
High-nitrate intervention
The 2×70 mL of nitrate-rich (i.e., 'high nitrate') beetroot juice contains 12.9 mmol nitrate (NO3-).
Low-nitrate intervention
The 2×70 mL of nitrate-depleted (i.e., 'low nitrate') beetroot juice contains 0.04 mmol (or less) nitrate.

Locations

Country Name City State
Austria Medical University of Vienna Vienna
Austria University of Vienna Vienna

Sponsors (5)

Lead Sponsor Collaborator
University of Vienna Edith Cowan University, Flinders University, Medical University of Vienna, Queensland University of Technology

Country where clinical trial is conducted

Austria, 

References & Publications (3)

Blekkenhorst LC, Bondonno NP, Liu AH, Ward NC, Prince RL, Lewis JR, Devine A, Croft KD, Hodgson JM, Bondonno CP. Nitrate, the oral microbiome, and cardiovascular health: a systematic literature review of human and animal studies. Am J Clin Nutr. 2018 Apr 1;107(4):504-522. doi: 10.1093/ajcn/nqx046. — View Citation

Raubenheimer K, Bondonno C, Blekkenhorst L, Wagner KH, Peake JM, Neubauer O. Effects of dietary nitrate on inflammation and immune function, and implications for cardiovascular health. Nutr Rev. 2019 May 30:nuz025. doi: 10.1093/nutrit/nuz025. Online ahead of print. — View Citation

Raubenheimer K, Hickey D, Leveritt M, Fassett R, Ortiz de Zevallos Munoz J, Allen JD, Briskey D, Parker TJ, Kerr G, Peake JM, Pecheniuk NM, Neubauer O. Acute Effects of Nitrate-Rich Beetroot Juice on Blood Pressure, Hemostasis and Vascular Inflammation Markers in Healthy Older Adults: A Randomized, Placebo-Controlled Crossover Study. Nutrients. 2017 Nov 22;9(11):1270. doi: 10.3390/nu9111270. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Change in clinical blood pressure Blood pressure Change from baseline clinical blood pressure at 4 weeks of the HI-NI intervention
Other Change in clinical blood pressure Blood pressure Change from baseline clinical blood pressure at 4 weeks of the LO-NI intervention
Other Change in plasma nitrate and nitrite Marker for nitrate bioavailability and functioning of the enterosalivary nitrate-nitrite-nitric oxide (NO) pathway Change from baseline plasma nitrate and nitrite at 4 weeks of the HI-NI intervention
Other Change in plasma nitrate and nitrite Marker for nitrate bioavailability and functioning of the enterosalivary nitrate-nitrite-nitric oxide (NO) pathway Change from baseline plasma nitrate and nitrite at 4 weeks of the LO-NI intervention
Other Change in blood monocyte-platelet aggregation Vascular inflammation biomarker Change from baseline blood monocyte-platelet aggregation at 4 weeks of the HI-NI intervention
Other Change in blood monocyte-platelet aggregation Vascular inflammation biomarker Change from baseline blood monocyte-platelet aggregation at 4 weeks of the LO-NI intervention
Other Change in high-sensitive plasma C-reactive protein (hsCRP) Inflammation biomarker Change from baseline plasma hsCRP at 4 weeks of the HI-NI intervention
Other Change in high-sensitive plasma C-reactive protein (hsCRP) Inflammation biomarker Change from baseline plasma hsCRP at 4 weeks of the LO-NI intervention
Primary Change in forearm blood flow (FBF) response to acetylcholine Vascular function Change from baseline FBF at 4 weeks of the HI-NI intervention
Primary Change in forearm blood flow (FBF) response to acetylcholine Vascular function Change from baseline FBF at 4 weeks of the LO-NI intervention
Primary Change in 24 hour-ambulatory systolic blood pressure Blood pressure Change from baseline 24 hour-ambulatory systolic blood pressure at 4 weeks of the HI-NI intervention
Primary Change in 24 hour-ambulatory systolic blood pressure Blood pressure Change from baseline 24 hour-ambulatory systolic blood pressure at 4 weeks of the LO-NI intervention
Secondary Change in granulocyte CD11b expression Vascular inflammation biomarker Change from baseline granulocyte CD11b expression at 4 weeks of the HI-NI intervention
Secondary Change in granulocyte CD11b expression Vascular inflammation biomarker Change from baseline granulocyte CD11b expression at 4 weeks of the LO-NI intervention
Secondary Change in forearm blood flow (FBF) response to glyceryltrinitrate Vascular function Change from baseline FBF at 4 weeks of the HI-NI intervention
Secondary Change in forearm blood flow (FBF) response to glyceryltrinitrate Vascular function Change from baseline FBF at 4 weeks of the LO-NI intervention
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A